Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
Cleary JM, Wang V, Heist RS, Kopetz ES, Mitchell EP, Zwiebel JA, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Meric-Bernstam F, Dillmon MS, Williams PM, Hamilton SR, Conley BA, Aguirre AJ, O'Dwyer PJ, Harris LN, Arteaga CL, Chen AP, Flaherty KT. Cleary JM, et al. Clin Cancer Res. 2021 Jun 1;27(11):2996-3004. doi: 10.1158/1078-0432.CCR-21-0066. Epub 2021 Feb 26. Clin Cancer Res. 2021. PMID: 33637626 Free PMC article. Clinical Trial.
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. Messersmith WA, et al. Among authors: cleary jm. Clin Cancer Res. 2015 Jan 1;21(1):60-7. doi: 10.1158/1078-0432.CCR-14-0607. Epub 2014 Sep 17. Clin Cancer Res. 2015. PMID: 25231399 Clinical Trial.
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD, Faessel HM, Berger AJ, Burke K, Mulligan G, Dezube BJ, Harvey RD. Sarantopoulos J, et al. Among authors: cleary jm. Clin Cancer Res. 2016 Feb 15;22(4):847-57. doi: 10.1158/1078-0432.CCR-15-1338. Epub 2015 Sep 30. Clin Cancer Res. 2016. PMID: 26423795 Clinical Trial.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI. LoRusso PM, et al. Among authors: cleary jm. Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3. Clin Cancer Res. 2016. PMID: 26842236 Free PMC article. Clinical Trial.
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Mouw KW, et al. Among authors: cleary jm. Clin Cancer Res. 2017 Jun 15;23(12):3214-3222. doi: 10.1158/1078-0432.CCR-16-2017. Epub 2016 Nov 16. Clin Cancer Res. 2017. PMID: 27852700 Free PMC article.
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Abramson VG, et al. Among authors: cleary jm. Clin Cancer Res. 2017 Jul 15;23(14):3520-3528. doi: 10.1158/1078-0432.CCR-16-1764. Epub 2016 Dec 28. Clin Cancer Res. 2017. PMID: 28031425 Clinical Trial.
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. Goyal L, et al. Among authors: cleary jm. Cancer. 2017 Jun 1;123(11):1979-1988. doi: 10.1002/cncr.30571. Epub 2017 Feb 13. Cancer. 2017. PMID: 28192597 Free PMC article. Clinical Trial.
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin Chessex A, Zanna C, Flaherty KT, Baselga J. Voss MH, et al. Among authors: cleary jm. Clin Cancer Res. 2019 May 1;25(9):2699-2707. doi: 10.1158/1078-0432.CCR-18-1959. Epub 2019 Feb 11. Clin Cancer Res. 2019. PMID: 30745300 Free PMC article. Clinical Trial.
Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Cleary JM, et al. Mol Cell. 2020 Jun 18;78(6):1070-1085. doi: 10.1016/j.molcel.2020.04.035. Epub 2020 May 26. Mol Cell. 2020. PMID: 32459988 Free PMC article. Review.
High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors.
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, Ni J, Chipashvili O, Hagan T, Pioso MS, McQueeney K, Ng K, Aguirre AJ, Cleary JM, Cocozziello D, Sotayo A, Ryan J, Zhao JJ, Letai A. Bhola PD, et al. Among authors: cleary jm. Sci Signal. 2020 Jun 16;13(636):eaay1451. doi: 10.1126/scisignal.aay1451. Sci Signal. 2020. PMID: 32546544 Free PMC article.
127 results